VivoSeq
Other

Catheter

0

Pipeline Programs↗

7

Active Trials↗

6

Companies Involved↗

Catheter is an early-stage landscape with 0 programs across 6 companies. The most active players are Regeneron, AbbVie, AMAG Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

65/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalA

AMAG Pharmaceuticals, Inc.

0 programs

PreclinicalN

NovaBay Pharmaceuticals, Inc.

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalA

Alev Keskin

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

49

clinical trials

Completed22 · 45%
Unknown status8 · 16%
Terminated7 · 14%
Withdrawn5 · 10%
Recruiting4 · 8%
Active, not recruiting1 · 2%
Other2 · 4%

Clinical Trials

Trial Activity

49 trials

Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
Recruiting·MMedstar Health Research Institute·Phase 2·NCT04323735·182 enrolled
Heparin vs Placebo for Cardiac Catheterization
Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 3·NCT04374799·1,623 enrolled
Heparinization vs Salinization of the Peripheral Venous Catheter
Recruiting·CConsorci Sanitari de l'Alt Penedès i Garraf·N/A·NCT05209841·3,450 enrolled
Superficial Vein Thrombosis of the Upper Limb in Bacteremia Associated With PICCline and Midline Catheters: Frequency and Clinical Consequences
Recruiting·CCentre Hospitalier Universitaire de Nice·Preclinical·NCT07388381·150 enrolled
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
Active, not recruiting·Regeneron logoRegeneron·Phase 2·NCT06299111·195 enrolled
Transcatheter Edge-to-Edge Repair In Moderate and Exertional-Induced Severe MR (TIMER)
Not yet recruiting·SSun Yat-sen University·Phase 1·NCT07197021·300 enrolled
Diphenhydramine in Catheter Related Bladder Discomfort
Enrolling by invitation·—·N/A·NCT06345261·104 enrolled
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Completed·GGeisinger Clinic·N/A·NCT01973036·201 enrolled
Safety of Catheter Lock With or Without Heparin in Implanted Central Venous Catheters
Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 4·NCT00994136·1,100 enrolled
Prophylactic Antimicrobial Catheter Lock
Completed·SSatellite Healthcare·Phase 4·NCT00571259·303 enrolled
PENG Block forTranscatheter Aortic Valve Implantation
Completed·MMedipol University·N/A·NCT05904912·40 enrolled
Norepinephrine Administration Through a Midline Catheter in an Intermediate Care Unit
Completed·—·N/A·NCT06121115·473 enrolled
Protamine Sulfate During Transcatheter Aortic Valve Implantation
Completed·MMedical University of Warsaw·Phase 4·NCT02974660·100 enrolled
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
Completed·CCancer Research Campaign Clinical Trials Centre·N/A·NCT00024297
Heparin Versus Normal Saline in Peripherally Inserted Central Catheter Lines
Completed·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT05029596·142 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)